NZ626485B2 - Novel therapeutic use of p75 receptor antagonists - Google Patents
Novel therapeutic use of p75 receptor antagonists Download PDFInfo
- Publication number
- NZ626485B2 NZ626485B2 NZ626485A NZ62648512A NZ626485B2 NZ 626485 B2 NZ626485 B2 NZ 626485B2 NZ 626485 A NZ626485 A NZ 626485A NZ 62648512 A NZ62648512 A NZ 62648512A NZ 626485 B2 NZ626485 B2 NZ 626485B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- lll
- alkyl
- atom
- compound
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title claims abstract description 20
- 229940044551 receptor antagonist Drugs 0.000 title claims abstract description 20
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 title claims abstract 5
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 86
- 206010020853 Hypertonic bladder Diseases 0.000 claims abstract description 17
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 17
- 208000020629 overactive bladder Diseases 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 41
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 34
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- -1 trifluoromethoxy radical Chemical class 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 19
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 16
- 150000007513 acids Chemical class 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 150000003254 radicals Chemical class 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- ZGEMSUUNLVFYPT-UHFFFAOYSA-N 1-(2-phenyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl)-2-(8-pyridin-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl)ethanone Chemical compound C1CC2=NN(C=3C=CC=CC=3)C=C2CN1C(=O)CN(C1)CC2CCC1N2C1=CC=CN=C1 ZGEMSUUNLVFYPT-UHFFFAOYSA-N 0.000 abstract 1
- CVRCENOFWCSYGS-AQDIUKAZSA-N 6-[(3r,5s)-3,5-dimethyl-4-[2-oxo-2-(2-phenyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl)ethyl]piperazin-1-yl]pyridine-3-carboxylic acid;hydrochloride Chemical compound Cl.N1([C@H](C)CN(C[C@@H]1C)C=1N=CC(=CC=1)C(O)=O)CC(=O)N(CC1=C2)CCC1=NN2C1=CC=CC=C1 CVRCENOFWCSYGS-AQDIUKAZSA-N 0.000 abstract 1
- GEHLJBYNRPSRFJ-KDURUIRLSA-N 6-[(3s,5r)-4-[2-[4-(1-benzofuran-7-yl)-3,6-dihydro-2h-pyridin-1-yl]-2-oxoethyl]-3,5-dimethylpiperazin-1-yl]pyridine-3-carboxylic acid Chemical compound C([C@@H](N([C@H](C)C1)CC(=O)N2CC=C(CC2)C=2C=3OC=CC=3C=CC=2)C)N1C1=CC=C(C(O)=O)C=N1 GEHLJBYNRPSRFJ-KDURUIRLSA-N 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 description 33
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 29
- 241000700159 Rattus Species 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 13
- 229910052731 fluorine Inorganic materials 0.000 description 13
- 230000027939 micturition Effects 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 208000005615 Interstitial Cystitis Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 125000003709 fluoroalkyl group Chemical group 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 230000003202 urodynamic effect Effects 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 206010011796 Cystitis interstitial Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920001774 Perfluoroether Polymers 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010005063 Bladder pain Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 239000004233 Indanthrene blue RS Substances 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241001523179 Lasia <small-headed fly> Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000036724 intravesical pressure Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000036453 micturition reflex Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Disclosed is the use of p75 receptor antagonist compounds of formula (I) for the preparation of a medicament for use in the treatment and/or prevention of overactive bladder. Examples of a compound of formula (I) are: 1-[4-(4-chloro-3-trifluoromethyl-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-[8-(5-fluoro-pyrimidin-2-yl)-3,8-diaza-bicyclo[3,2,1]oct-3-yl]-ethanone 6-{(3S,5R)-3,5-Dimethyl-4-[2-oxo-2-(2-phenyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethyl]piperazin-1-yl}nicotinic acid hydrochloride 6-{(3S,5R)-4-[2-(4-benzofuran-7-yl-3,6-dihydro-2H-pyridin-1-yl)-2-oxoethyl]-3,5-dimethylpiperazin-1-yl}nicotinic acid 1-(2-phenyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)-2-(8-pyridin-3-yl-3,8-diazabicyclo[3,2,1]oct-3-yl)ethanone 5-fluoro-pyrimidin-2-yl)-3,8-diaza-bicyclo[3,2,1]oct-3-yl]-ethanone 6-{(3S,5R)-3,5-Dimethyl-4-[2-oxo-2-(2-phenyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethyl]piperazin-1-yl}nicotinic acid hydrochloride 6-{(3S,5R)-4-[2-(4-benzofuran-7-yl-3,6-dihydro-2H-pyridin-1-yl)-2-oxoethyl]-3,5-dimethylpiperazin-1-yl}nicotinic acid 1-(2-phenyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)-2-(8-pyridin-3-yl-3,8-diazabicyclo[3,2,1]oct-3-yl)ethanone
Description
NOVEL THERAPEUTIC USE OF P75 RECEPTOR NISTS
The subject of the present invention is the use of p75 receptor nists for the
preparation of medicaments for use in the treatment and/or prevention of overactive
bladder and other urinary disorders.
Overactive bladder syndrome (sometimes called an able' bladder or sor
instability') is a common condition terized by repeated and uncontrolled bladder
contractions. Symptoms include urgency, frequency, nocturia and urge incontinence.
Their causes are not fully understood although they are partially due to the defective
our of the detrusor. Bladder training is usually the main treatment, and medication
(including antimuscarinic agents) does generally not alleviate all symptoms.
Urinary disorders may include, but are not limited to, inence (inability to
control urine flow), interstitial cystitis (IC), bladder pain syndrome (BPS), benign prostate
lasia (PBH), cancers of the urinary tract; some of them can have serious, even life-
threatening, complications.
It is therefore highly desirable to provide new medicines for the treatment and/or
prevention of the above disorders.
The compounds according to the present invention have an affinity for the p75
neurotrophin receptor.
Neurotrophins belong to a family of proteins of which the biological effect is in
particularsurvival, development and function of neurons.
The p75 receptor, which is the receptor for all rophins, is a transmembrane
glycoprotein of the tumoral necrosis factor (TNF) receptor family (W.J. Friedman and
LA. Greene, Exp. Cell. Res., (1999), 253, 131-142). The p75 receptor is expressed in
several cell types, and several biological ons have been attributed to said receptor:
firstly, modulation of the affinity of neurotrophins for receptor tyrosine kinases (trk);
secondly, in the absence of trk, induction of a signal for cell death by sis. Moreover,
the neurotrophin precursors, proneurotrophins, are capable of binding to p75 with a high
ty, and are considered to be powerful inducers of p75 dependent apoptosis in
neurons and certain cell lines.
The p75 receptor is a key component in the process of cell survival/proliferation or
death, not only in the central s system but also in a number of peripheral s
like nerves, liver, bladder muscles and prostate. This pleiotropic receptor has multiple and
even opposite functions, which likely depend on the cell and tissue type, as well as on the
physio-pathological status of the organism. It has been observed that mice selectively
over sing bladder Nerve Growth Factor exhibited: increased bladder wall
ation, decreased bladder capacity, more frequent ition, increased non-voiding
bladder contractions; all consistent with an overactive bladder (OAB) phenotype d
BM and al “Neurotrophin/receptor expression in urinary bladder of mice with
overexpression of NGF in urothelium” Am J Physiol Renal Physiol. 300: F345—F355,
(2011)).
It has also been observed that in humans with obstructed bladders or those with
interstitial cystitis or bladder pain me (lC/BPS), tissue levels of NGF are elevated
compared to healthy controls (Steers WD and Tuttle JB, Nat Rev Urol (2006), vol 3(2),
101-110; Liu HZ et al. (2009), BJUI 104, 1476-1481).
p75 ors and Trks ors are expressed throughout the rat urinary r
and are present in nerve fibers of the detrusor smooth muscle, the suburothelial nerve
plexus, urothelial cells, and nerve fibers associated with the suburothelial bladder
vasculature (Klinger MB and al”p75NTR Expression in Rat Urinary Bladder Sensory
Neurons and Spinal Cord with Cyclophosphamide—lnduced Cystitis” J. Comp. Neurol. 507:
1379—1392, (2008)).
p75 receptors pression on detrusor smooth muscle cells altogether with
overexpression of NGF could play a deleterious role on the functionality of detrusor
muscle.
According to a first , the present invention provides for the use of a p75
receptor antagonist in the preparation of medicaments for use in the treatment and/or
prevention of overactive bladder and other y ers.
In the present patent application the terms “use of a p75 receptor antagonist in the
preparation of medicaments” have to be understood as synonyms of the terms “a p75
receptor antagonist for the preparation of a medicament for use”, or “a p75 receptor
antagonist for use”, or “a p75 receptor antagonist for use as a medicament”
According to another object of the invention, the present ion provides for the
use of a p75 receptor antagonist of the following general formula (I):
,0) (I)
(I) / (CH2)n-W-R5
A N—( (I)
) O
m (I)
in which:
- m") represents 0 or 1;
- A") represents:
R20(I)
and B") ents a hydrogen atom
A") represents a hydrogen atom and B") represents:
(01/
R2 |
W(')--is a nitrogenous heterocycle chosen from:
- 1-3 represents 1, 2 or 3;
- n") represents 1 or 2;
- R1") represents a n atom, a (C1-C4)alkyl group, a trifluoromethyl radical, a (C1-
C4)alkoxy group or a trifluoromethoxy radical;
- R2") represents a hydrogen atom, a halogen atom, a (C1-C4)alkyl group, a
oromethyl radical, a (C1-C4)alkoxy group, a trifluoromethoxy radical, a COOR“) group
or a CONH2 group;
- R5") represents a group of formula:
N\ R4 R4
\ R30) (l) N
I (I)
R? (I) R3
R3 //N
N R40) N R40 N , N
\ (I)
0U R3
N R4
in which R3") and R4"), located on any one of the available positions, independently
represent a hydrogen atom, a halogen atom, a (C1-C4)alkyl or (C1-C4)alkoxy group, a
trifluoromethyl or trifluoromethoxy radical, a cyano, or a COOH, COO(C1-C4)alkyl, CONH2,
CONR6“) R7") or NHCOR‘” group;
- R"), R6") and R7") represent independently of each other a (C1-Ce)alkyl group;
in the preparation of medicaments for use in the treatment and/or tion
overactive bladder.
The compounds of Formula (I) may contain one or more asymmetrical carbon
atoms. They may therefore exist in the form of enantiomers or of reoisomers. These
enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures,
are part of the invention.
The compounds of Formula (I) may exist in the form of bases or addition salts with
acids. Such addition salts are part of the ion.
These salts may be prepared with pharmaceutically acceptable acids, but the salts
of other acids that are useful, for example, for purifying or isolating the compounds of
Formula (I) are also part of the invention.
In the context of the compounds of general formula (I):
- the term “a halogen atom” is intended to mean: a fluorine, a chlorine, a bromine
or an iodine;
-the term “an alkyl group” is intended to mean: a linear or branched, saturated
aliphatic group. By way of examples, mention may be made of a C1-C4 alkyl group that
may represent a methyl, ethyl, propyl, isopropyl, butyl, yl or tert-butyl;
- the term “a alkyl group” is intended to mean: an alkyl group of which one or
more of the hydrogen atoms has (have) been substituted with a fluorine atom;
- the term “a perfluoroalkyl group” is ed to mean: an alkyl group of which all
the hydrogen atoms have been substituted with a ne atom, for e trifluoroalkyl;
- the term “an alkoxy group” is intended to mean: an —O-alkyl radical where the
alkyl group is as defined above.
These compounds and their method of ation are described in
W02009/150388 (U82011/144116), from which the content is included herein by
reference.
According to another object of the invention, the present invention provides for the
use of a p75 receptor antagonist of the following general formula (II):
(II) 0
B K
(II)
A(||)/ _<\(CH2)n(II)_ N/ N\_/N—R3
( )Nm (II)0
(II)
in which:
- m(”) is 0 or 1;
-A(”) is:
and 8"" is a hydrogen atom
or
AU” is a hydrogen atom and 8"" is:
(ll)r‘/
R2 |
- R1”) and R2("), which may be identical or different, are independently a hydrogen or
halogen atom, a (C1-C4)alkyl, (C1-C4)fluoroalkyl, (C1-Cz)perfluoroalkyl or )alkoxy
group or a trifluoromethoxy group;
- n(”) is 1 or 2;
- R3”) is a group of formula:
N R53”) R5(II) N%R4 {Eon(H) 5(II)
where R4(”) and R5("), which may be identical or different, are located on any ble
positions and are ndently a hydrogen or halogen atom, a hydroxyl, a (C1-C4)alkyl,
(C1-C4)fluoroalkyl, (C1-Cz)perfluoroalkyl or )alkoxy group, a trifluoromethoxy group,
a cyano group, or a COOH, COO(C1-C4)alkyl, CONHZ, CONR6(”') R7('”) or NHCOR"”’
group;
- R"", R6“) and R7(”) are independently of each other a (C1-Ce)alkyl group;
in the preparation of medicaments for use in the treatment and/or prevention
overactive r.
The nds of formula (II) may se one or more asymmetrical carbon atoms.
They may therefore exist in the form of enantiomers or diastereoisomers. These
enantiomers and diastereoisomers and also mixtures thereof, including racemic mixtures,
form part of the invention.
The compounds of formula (II) may exist in the form of bases or of addition salts with
acids. Such on salts form part of the invention.
These salts may be prepared with pharmaceutically acceptable acids, but the salts of
other acids that are useful, for example, for purifying or isolating the compounds of
formula (II) also form part of the invention.
In the context of the nds of general formula (II):
- the term “a halogen atom” is intended to mean: a fluorine, a chlorine, a bromine
or an iodine;
- the term “an alkyl group” is intended to mean: a linear or branched, saturated
aliphatic group. By way of examples, mention may be made of a C1-C4 alkyl group which
may represent a methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl;
- the term “a fluoroalkyl group” is intended to mean: an alkyl group of which one
or more hydrogen atoms have been substituted with a fluorine atom;
- the term “a perfluoroalkyl group” is intended to mean: an alkyl group of which all
the en atoms have been substituted with a fluorine atom;
- the term “an alkoxy group” is ed to mean: an —O-alkyl group where the
alkyl group is as defined above.
These compounds and their method of preparation are described in
W02009/150387 (U82011/144122), from which the content is included herein by
reference.
According to another object of the invention, the present invention provides for the
use of a p75 receptor antagonist of the following general formula (III):
Ail”) n
(Ill)
W—RZ
(III)
in which:
-A(”') represents a group:
(III)
R1 (”I)
(”D 4 4‘ (III)
(III) t ,
XR17<Xuma“ N
- n('”) represents 1 or 2;
- m('”) represents 0 or 1;
- Y('”) represents a carbon, nitrogen, sulphur or oxygen atom or a single or double bond;
- X0”), X10”) and X20”) represent a carbon, en, sulphur or oxygen atom, it being
understood that at least one of X0”), X1('”) and X2('”) is other than a carbon atom;
- RU”) and R1(”'), located on any one of the available positions, independently ent a
hydrogen atom, a halogen atom, a (C1-C4)alkyl group, a (C1-C4)alkoxy group, a
perfluoroalkyl radical, a trifluoromethoxy radical, a cyano, or a COOH, COO(C1-C4)alkyl,
CONR5<”'> R6('”) or NHCOR5<”'> group;
or R1('”) ents a group chosen from:
(m) (III)
(III) (III) (III)
(III) R3 R3 R3 R3
(In) (m) (m)
/ / / (m) /
R4 R4 | mm R4 NW
\ N R40\N’N NWN K/N
(III)
(In)
R3 R3
(III)R45 (III)
\ S \ O
the definition of R0”) remaining unchanged;
- R3('”) and R4(”'), d on any one of the available positions, independently represent a
hydrogen atom, a halogen atom, a (C1-C4)alkyl group, a (C(C1-C4)-C4)alkoxy group, a
perfluoroalkyl radical, a trifluoromethoxy radical, a cyano, or a COOH, COO(C1-C4)alkyl,
CONR5I'”) R6(”') or NHCORSI'”) group;
- WI'”) - is a nitrogenous heterocycle chosen from:
(Ill)
2 1-2
j:R5 Z (z-)—\
\_I_/N— —N( —
— (131-2— — 1g) — —N N—
R6 (“D \<
- 1-2 represents 1 or 2;
- 1-3 represents 1, 2 or 3;
- R20”) ents a group of formula:
48:7(()l” J:::3L8((III (III)
(II)I I(II) \ (III) /
(III R7
R7 {\NNéR {1R7NX’NUII) E130”)
8(|(|)| N
R8 R8
R
- R70”) and R8(”'), located on any one of the available positions, independently represent a
en atom, a halogen atom, a (C1-C4))alkyl group, a (C1-C4)alkoxy group, a
trifluoromethyl radical, a trifluoromethoxy radical, a cyano, or a COOH, COO(C1-C4)alkyl,
COO(C1-C4)cycloalkyl, SO(C1-C4)alkyl, 802(C1-C4)alkyl, CONH2, CONR5I'”) R6"”’ or
NHCOR5I'”) group;
or one of R70”) and R80”) represents a heterocycle chosen from:
(m) 60“) 6(III) R60“) (III)
i6 Rs
N N
II 4V: R6l l
_EN II —E
N/N [(1% N\
Z(III) 20“)
(III)
(III) (III) R60”)
(III) 7 R6
R6 R6N R6
N All—LN NtN
w I3 w MN\ \ (III) Z(III) z
“) 2(III) 20”) 20”)
”)
- 2"”) represents an oxygen or sulphur atom;
- R50”) and R60”) represent a hydrogen or a C1-C6 alkyl group;
in the ation of medicaments for use in the treatment and/or prevention
tive bladder.
The compounds of formula (III) may comprise one or more asymmetrical carbon
atoms. They may therefore exist in the form of enantiomers or reoisomers. Th ese
enantiomers and diastereoisomers, and also mixtures thereof, ing racemic
mixtures, form part of the invention.
The compounds of formula (III) may exist in the form of bases or of addition salts
with acids. Such addition salts form part of the in vention.
These salts may be prepared with pharmaceutically acceptable acids, but the salts
of other acids that are useful, for example, for purifying or isolating the compounds of
formula (III) also form part of the invention.
In the context of the compo unds of general formula (III):
- the term "a halogen atom" is intended to mean: a fluorine, a chlorine, a
bromine or an iodine;
- the term "an alkyl group" is ed to mean: a linear or branched saturated
aliphatic group. By way of example s, mention may be made of a C1 -C4 alkyl group which
may represent a methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert -butyl ;
- the term "a fluoroalkyl group" is intended to mean: an alkyl group of which one
or more hyd rogen atoms have been substituted with a fluorine atom;
- the term "a perfluoroalkyl group" is ed to mean: an alkyl group of which
all the hydrogen atoms have been substituted with a fluorine atom, for example a
trifluoroalkyl group such as trifluor omethyl;
- the term "an alkoxy group" is ed to mean: an -O-alkyl radical where the
alkyl group is as defined above;
- the term "a perfluoroalkoxy group" is intended to mean: an alkoxy group of
which all the hydrogen atoms have been substituted with a ne atom, for example a
trifluoroalkoxy group such as trifluoromethoxy;
- the term "a cycloalkyl group" is intended to mean: a cyclic alkyl group. By way
of examples, mention may be made of cyclopropyl, methylcyclopropyl, utyl,
cyclopentyl, cyclohexyl, etc., groups.
- the term "a halogen atom" is intended to mean: a fluorine, a chlorine, a
bromine.
These compounds and their method of preparation are described in
/080444 (U82012/245149), from which the content is included herein by
reference.
According to another object of the invention, the present invention provides for the
use of a p75 receptor antagonist of the following general formula (IV):
(IV)
('V) (IV)
(IV) / (CH )n-W-R2
A N—\( 2
(IV)
) O
m(IV)
(IV)
in which:
- nW) represents 1 or 2;
- m‘ ents 0 or 1;
- AW) ents a fused heterocyclic group of formula (Y('V))
(IV)
99%/ R1
(Iv)
R (IV)
(IV)
(Y)
and BUV) represents a hydrogen atom;
AW) represents a hydrogen atom; and
BUV) represents a fused heterocyclic group of formula (Y('V))
(IV)
(IV) (IV)
/ R1
R (IV)
(IV)
The fused heterocycle of formula Y‘“0 may be ed to the rest of the molecule via any
of the available carbon atoms, and in which:
- Ul'V) completes:
- either an aromatic or ted 6-atom nucleus, containing one or two nitrogen
atoms, the nucleus possibly being substituted with one or two halogen atoms, one or two
(C1-C4)alkyl or (C1-C4)alkoxy groups, or one or two perfluoroalkyl ls;
-or an aromatic or saturated 5-atom nucleus, containing a nitrogen, oxygen or
sulfur atom, the nucleus possibly being substituted with one or two (C1-C4)alkyl ;
- Xl'V) and X1('V) represent independently of each other CH or N;
- Rl'V) and R1('V) located on any of the available positions, independently represent a
hydrogen atom, a halogen atom, a (C1-C4)alkyl group, (C1-C4)alkoxy, a oroalkyl or
trifluoromethoxy radical, a cyano or a COOH, COO(C1-C4)alkyl, CONR3('V)R4('V) or
NHCORBW) group;
-W('V)- is a nitrogenous heterocycle chosen from:
1-2 (IV) 1-2
1_2 1_2 1-2
(Ia—)Rs (d—\
—N N— —N( —
_3 l_ _ _ _N
R4(IV) <
- 1-2 represents 1 or 2;
- 1-3 represents 1, 2 or 3;
- RZW) represents a group of formula:
48w: i 3% fig” {1R5 €®N\ (IV) \ \N \ (IV) / (IV)
(IV) R5
N R6 N N >2
R6 ('V) R6 (IV) R6 (IV)
N R6 ('V)
- in which R5('V) and R6('V), located on any of the available positions, independently
represent a hydrogen atom, a halogen atom, a (C1-C4)alkyl or )alkoxy group, a
trifluoromethyl or trifluoromethoxy radical, a cyano or a group COOH, COO(C1-C4)alkyl,
COO( C1-C4)cycloalkyl, SO( C1-C4)alkyl, S02( alkyl, CONR3 (IV) R4 (IV) ,
NR3 (IV) R4 (IV) or NHCOR3 (IV) ;
or one of the groups R5 (IV) and R6 (IV) may also represent a heterocycle chosen from:
- Z(IV) represents an oxygen or sulfur atom;
- R3(IV) and R4 (IV) represent a hydrogen or a C 1C6 alkyl group;
in the preparation of medicaments for use in the treatment and/or prevention
overactive r.
The compounds of formula (IV) may comprise one or more asymmetric carbon atoms.
They may thus ex ist in the form of enantiomers or reoisomers. These enantiomers
and diastereoisomers, and also mixtures thereof, ing racemic mixtures, form part of
the invention.
The compounds of formula (IV) may exist in the form of bases or of acid -addition salts.
Such addition salts form part of the invention.
These salts may be prepared with pharmaceutically acceptable acids, but the salts of
other acids that are useful, for example, for purifying or isolating the compounds of
formula (IV) also form part of the invention.
In the context of the compounds of general formula (IV), the ing definitions apply:
- a halogen atom: a fluorine, a chlorine, a bromine or an ;
- an alkyl group: a saturated, linear or branched aliphatic group. Examples that
may b e mentioned include a group (C1 -C4)alkyl which may represent a methyl, ethyl,
propyl, isopropyl, butyl, isobutyl or tert -butyl ;
- a fluoroalkyl group: an alkyl group in which one or more hydrogen atoms have been
replaced with a fluorine atom;
-a perfluoroalkyl group: an alkyl group in which all the hydrogen atoms have been
replaced with a fluorine atom, for example trifluoroalkyl;
- an alkoxy group: a radical -O-alkyl in which the alkyl group is as d previously;
- a perfluoroalkoxy group: an alkoxy group in which all the hydrogen atoms have been
ed with a fluorine atom, for example trifluoroalkoxy;
-a cycloalkyl group: a cyclic alkyl group. Examples that may be mentioned include
cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc., groups.
These compounds and their method of preparation are described in
/080445 2/245150), from which the content is included herein by
reference.
According to another object of the ion, the present invention provides for the
use of a p75 receptor nist selected from:
- compound n°1: 1-[4-(4-chlorotrifluoromethyl-phenyl)—3,6-dihydro-2H-pyridinyl]
[8-(5-fluoro-pyrimidinyl)-3,8—diaza-bicyclo[3.2.1]octyl]—ethanone ;
- compound n°2: 6-{(3S,5R)—3,5-Dimethyl[2-oxo(2-phenyl-2,4,6,7-
tetrahydropyrazolo[4,3-c]pyridinyl)ethyl]piperazinyl}nicotinic acid hydrochloride;
- compound n°3: 6-{(3S,5R)—4-[2-(4-benzofuranyl-3,6-dihydro-2H-pyridinyl)
oxoethyl]—3,5-dimethylpiperazinyl}nicotinic acid;
- compound n°4: 1-(2-phenyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridinyl)—2-(8—pyridin-
3-yl-3,8—diazabicyclo[3.2.1]octyl)ethanone;
the above compounds can also exist in the form of a base or of an addition salt with an
acid;
in the preparation of medicaments for use in the treatment and/or prevention
tive bladder.
These compounds and their mode of preparation are respectively described as
compound n°11 in W02009/150388 for compound n°1, as nds n°21 and n°28 in
W02011/O80444 ((U82012/245149)) for compounds n°2 and n°4 and as compound n°57
in W02011/080445 (U82012/245150) for compound n°3, from which the t is
included herein by reference.
The following table describes the structure of these compounds.
Compound n° Structure
1 7
Cl N/
)J N OH
/\ /N/§
7 O
i N N\///
\o )J N OH
4 FF
Said p75 receptor nists above, and the pharmaceutically acceptable salts
thereof, may be used at daily doses of 0.1 to 200 mg per kilo of body weight of the
mammal to be treated, preferably at daily doses of from 0.5 to 100 mg/kg. In humans, the
dose may vary preferably from 0.5 mg to 50 mg per day, in particular from 1 to 30 mg,
depending on the age of the individual to be treated, the type of treatment, prophylactic or
curative, and the seriousness of the er. Said p75 or antagonists are generally
administered as a dosage unit of 0.5 to 50 mg, preferably of 1 to 30 mg, of active principle,
one to five times a day. Preferable unit dosage forms comprise 1 or 30 mg of p75 receptor
antagonists.
Said dosage units are preferably formulated in pharmaceutical compositions in
which the active principle is mixed with a pharmaceutical ent.
In the pharmaceutical compositions of the present invention, use can me made for
oral, sublingual, subcutaneous, intramuscular, intravenous, topical, transdermal or rectal
administration.
Said p75 receptor antagonists, and the pharmaceutically acceptable salts thereof,
may be administered in unit administration forms, mixed with tional pharmaceutical
supports, to animals and humans for treating the abovementioned disorders. The unit
administration forms which are le comprise oral forms such as tablets, gel capsules,
s, granules and oral solutions or suspensions, sublingual and buccal
administration forms, subcutaneous, uscular or intravenous administration forms,
local administration forms and rectal administration forms.
When a solid composition in the form of tablets is ed, the main active
ingredient is mixed with a pharmaceutical vehicle such as n, starch, lactose,
magnesium stearate, talc, gum arabic or the like. The tablets may be coated with sucrose
or other suitable materials, or they may be treated such that they have sustained or
delayed activity and that they release, in a continuous , a predetermined amount
of active principle. Usual excipients include lactose monohydrate, microcrystalline
cellulose, povidone, sodium carboxymethylstarch, magnesium stearate, ethylcellulose,
hypromellose, macrogol 400, titane dioxide.
A preparation of gel capsules is obtained by mixing the active ingredient with a
diluent and pouring the mixture obtained into soft or hard gel capsules.
A preparation in the form of a syrup or elixir may n the active ingredient
together with a sweetener, preferably a calorie-free sweetener, methylparaben and
propylparaben as antiseptics, and also a flavour enhancer and a le colorant.
The dispersible powders or granules may contain the active ingredient mixed
with dispersing agents or wetting agents, or ding agents, such as
polyvinylpyrrolidone, and also with ners or flavour correctors.
For local administration, the active principle is mixed into an excipient for preparing
creams or ointments, or it is dissolved in a vehicle for intraocular administration, for
example in the form of an eyewash.
For rectal stration, use is made of suppositories prepared with binders which
melt at rectal ature, for e cocoa butter or polyethylene glycols.
For parenteral administration, s suspensions, saline solutions or injectable
sterile solutions which contain pharmacologically compatible dispersion agents and/or
wetting agents, for example propylene glycol or butylene glycol, are used.
The active principle may also be formulated in the form of microcapsules, optionally with
one or more supports or additives.
According to another object, the present invention provides a method of treating
and/or preventing overactive bladder or other urinary disorders in a patient which
comprises administering to a patient in need of such treatment or tion a
therapeutically effective amount of a p75 receptor antagonist. In one aspect, the p75
receptor antagonist is selected from a compound of general formula (I), a nd of
general formula (II), a compound of general a (III), and a compound of the following
general formula (IV). In another , the p75 receptor antagonist is selected from the
group consisting of compound n°1: 1-[4-(4-chlorotrifluoromethyl-phenyl)—3,6-dihydro-
2H-pyridiny|][8—(5-fluoro-pyrimidinyl)—3,8—diaza-bicyclo[3.2.1]octyl]—ethanone;
compound n°2: 6-{(3S,5R)—3,5-Dimethyl[2-oxo(2-phenyl-2,4,6,7-
tetrahydropyrazolo[4,3-c]pyridinyl)ethyl]piperaziny|}nicotinic acid hydrochloride;
compound n°3: 6-{(3S,5R)—4-[2-(4-benzofuranyl-3,6-dihydro-2H-pyridinyl)
oxoethyl]—3,5-dimethylpiperaziny|}nicotinic acid; and compound n°4: 1-(2-phenyl-
2,4,6,7-tetrahydropyrazolo[4,3-c]pyridinyl)—2-(8—pyridinyl-3,8—diazabicyclo[3.2.1]oct
yl)ethanone; the above compounds can also exist in the form of a base or of an addition
salt with an acid.
As used herein, the term peutically effective amount” is meant to describe an
amount of a compound, ition, medicament or active ingredient effective in
producing the desired therapeutic effect.
The following examples further illustrate the present invention.
EXAMPLES
Brief description of the drawings
Figure 1 is a cystometrogram (CMG) from a rat during the light phase in response to
continuously-infused saline, in normal filling-voiding micturition cycle.
Figure 2 shows the effect of the compounds on intercontraction intervals (lCl) in SHR
male rats, characterized by overactive bladder (OAB).
Figure 3 represents the positive activity of the compounds according to the invention on
bladder capacity of SHR male rats.
Figure 4 shows the dose response activity (3, 10, 30 mg/kg po) of compound 2 on
ontraction intervals in SHR male rats.
Figure 5 represents the dose ent activity of compound n°2 on bladder ty in
SHR male rats.
Figure 6 shows the effect of a one-week treatment with nd n°2 on intercontraction
intervals (lCl) in SHR male rats.
Figure 7 shows the effect of a one-week ent with compound n°2 on bladder
capacity in SHR male rats.
General methods
Animal preparation
Male adult SHR/N lco rats (250g; Charles River ltaly), were housed 7 days prior to the
surgery with free access to standard chow and water. Animals were used in accordance
with sanofi international ethical code and the international principles governing the care
and treatment of laboratory animals, (E.E.E Council Directive 86/609, DJL358, 1 Cec. 12,
1987) in a fully ited AAALAC facility.
All efforts were made to minimize the potential for animal pain, stress, or distress.
A lower midline abdominal incision was performed under general anesthesia with 2—3%
isoflurane using aseptic techniques. Their body temperature was maintained at 37° C
using a homeothermic blanket. Polyethylene tubing was inserted into the dome of the
bladder and secured in place with a 6—0 nylon purse-string suture. The distal end of the
tubing was sealed, ed subcutaneously, and alized at the back of the neck, out
of the animal's reach. At the moment of the surgery animals were 16 weeks old.
Cystometry
After one week from surgery, animals were placed in a Small Animal Cystometry Lab
Station (MED Associates, St. , Vermont) for urodynamic measurements. Prior to
the start of recording the bladder was emptied and the catheter was connected via a T-
tube to a pressure transducer and microinjection pump. ic saline (0.9% NaCl at
room ature) was d into the bladder at a rate of 10 ml per hour. An analytical
balance beneath the wire-bottomed animal cage measured the amount of urine voided
during continuous cystometry. A single cystometrogram is defined as the simultaneous
recording of intravesical pressure, infused volume and voided volume during a single
g-voiding cycle. At least 4 reproducible micturition cycles are recorded (basal period)
after the initial stabilization period of 25 to 30 minutes, using MED-CMG software
(Catamount Research &Development Company).
Then, vehicle or compounds were administered orally at 2 ml/kg.
Due to kinetic profile of compounds, urodynamic ment was performed 1h after
ent and at least 4 ucible micturition cycles were recorded.
Experiments were performed at similar times of day to avoid the possible impact of
circadian rhythm variations (Herrera and al “Diurnal variation in Urodynamics of rat.” PLoS
ONE 5(8) (2010)). At the end of experiments, animals were iced with an se of
pentobarbital.
Data analysis
The cystometrograms are analyzed using a specific software, SOF-552 cystometry data
analysis.
The following endpoints have been considered (Figure 1):
1. ontaction intervals (sec) (lCl) - Time between micturition events (micturition
interval)
2. Threshold pressure (mmHg) (TP) - Bladder pressure ately prior to
micturition
3. m bladder pressure (mmHg) (Max P) -Highest bladder pressure associated
with voiding
4. Minimum bladder pressure (mmHg) (Min P) - Lowest bladder pressure during
bladder filling
. lnfused volume (ul) (lnf. Vol) e of saline infused during the micturition cycle
6. Average bladder pressure (mmHg) (Aver P) - Average bladder pressure during
bladder filling
Exclusion Criteria
Rats were removed from study, before any treatment when adverse events occurred that
included: a reduction in body weight urgery, lethargy superior or equal to 20%, pain,
or distress not relieved by sanofi’s approved regimen of postoperative analgesics or
hematuria.
Animals with atypical micturition pattern are excluded from the study.
Expression of data and statistical analysis
In order to limit the impact of inter-group or intra-group variability, all data were expressed
as % of l period (100%), as mean i rd error of mean (SEM) and were
averaged per group of treatment. A one way analysis of variance ), followed by
Newman-Keuls’ test or Dunnett’s test, were used. A probability value of p<0.05 was
regarded as significant.
EXAMPLE 1: Effects of an acute treatment with p75 antagonists on amic
parameters in SHR rats characterized by spontaneous overactive bladder (OAB).
Drugs
Vehicle: 0.5% Polysorbate 80 (P880) solution in buffered methylcellulose (MC 0.6%)
Compound n°1 at 10 mg/kg: suspension (0.5% P880 plus MC 0.6%)
Compound n°2 at 3, 10, 30 mg/kg: suspension (0.5% P880 plus MC 0.6%)
nd n°3 at 10 mg/kg: suspension (0.5% P880 plus MC 0.6%)
Compound n°4 at 10 mg/kg: suspension (0.5% P880 plus MC 0.6%)
Experimental design:
In order to investigate the role of compounds according to the invention in the micturition
pathway, 5 groups of 4-12 rats are used:
Group 1, e per os (po) (n=10)
Group 2, Compound n°1 at 10 mg/kg po (n=12)
Group 3, Compound n°2 at 10 mg/kg po (n=6)
Group 4, Compound n°3 at 10 mg/kg po (n=4)
Group 5, nd n°4 at 10 mg/kg po (n=5)
In order to perform a dose response of Compound n°2 (330 mg/kg), 4 groups of 6-9
rats are used:
Group 1, Vehicle po (n=8)
Group 2, Compound n°2 at 3 mg/kg po (n=7)
Group 3, Compound n°2 at 10 mg/kg po (n=6)
Group 4, Compound n°2 at 30 mg/kg po (n=9)
1. RESULTS
In order to limit the impact of inter-group or intra-group variability that existed; the data
have been expressed as percentage of control values.
1. The compounds at 10 mg/kg po sed the |C| (intercontraction intervals) and
the bladder capacity ed volume)
For |C| (Figure 2)
e 111.7 i 10.3 %, compound n°1, 195.5: 15.4 %, compound n°2, 10 mg/kg po
199.7 i 28.5%, compound n°3, 10 mg/kg po 167.2 i 20.3%, compound n°4, 10
mg/kg po 186.3 i 26.9%
For Infused volume (Figure 3)
Vehicle 111.7 i 10.3 %, compound n°1, 194.9: 15.3 %, compound n°2, 10 mg/kg po
198.9 i 28.3%, nd n°3, 10 mg/kg po 167.14 i 20%, compound n°4, 10 mg/kg
po 186.2 i 26.9%
2. The compounds at 10 mg/kg po sed the lCl (intercontraction intervals) and
the bladder ty (infused volume) dose dependently
For lCl (Figure 4)
Vehicle 114.3 i 12.01 %, compound n°2, 3 mg/kg po 160.9 i 21.8%, compound n°2,
mg/kg po 199.7 i 28.5%, compound n°2, 30 mg/kg po 210.5 i 24.7%
For Infused volume (Figure 5)
Vehicle 114.3 i 12 %, compound n°2, 3 mg/kg po 160.8 i 21.7%, compound n°2, 10
mg/kg po 198.9 i 28.3%, compound n°2, 30 mg/kg po 209.9 i 24.5%.
2. CONCLUSION
The compounds increased the lCl and the bladder capacity in this pathophysiological
model. The compounds had no effect on micturition pressure parameters suggesting a
specific response. These compounds can thus be useful for the treatment and/or
prevention of overactive bladder.
E 2: Effects of one-week chronic treatment with a p75 antagonist on
urodynamic parameters in SHR rats characterized by spontaneous overactive
bladder (OAB).
Drug:
Compound n°2 at 10 mg/kg: suspension (0.5% P880 plus MC 0.6%)
The treatment started at least 5 days after surgery, and lasted 7 days. The cystometry test
was med 24 h after the end of the last treatment.
Experimental design:
2 groups of 14-15 rats were constituted:
0 Control rats vehicle d vehicle 7 days
0 Treated rats 7 days with compound n°2 at 10 mg/kg/2ml po
For avoiding numerosity ms linked to loss of intrabladder—catheter, 30% animals
more were used in this experiment.
1. RESULTS
In order to limit the impact of inter-group or intra-group variability that existed; the data
have been expressed as percentage of control values.
For ICI e 6) Vehicle 122.5 i10.15 %, compound n°2, 173.8 i 21.1%,
For Infused volume (Figure 7) Vehicle 339.90 i 28.07 %, compound n°2 173.7 i 21.1
2. CONCLUSION
The chronic treatment (one week) with a p75 antagonist, affects the micturition reflex in
SHR rats, characterized by DO-OAB. The compound n°2 increased the ICI and the
bladder capacity in this pathophysiological model. The compound had no effect on
micturition pressure parameters ting a ic response. This compound can thus
be useful for the treatment and/or prevention of overactive bladder.
Pharmaceutical composition according to the invention
As a representative example, a unitary dosage form of a compound of the invention
in the form of a tablet may comprise the following constituents:
p75 receptor antagonist 5,0 mg
Lactose 122,0 mg
ristalline ose 36,0 mg
Sodium ymethylstarch 7,0 mg
Polyvidone 9 mg
Magnesium stearate 1,0 mg
Claims (2)
1. Use of a p75 receptor antagonist in the preparation of medicaments for use in the treatment and/or prevention of overactive bladder, n said p75 receptor antagonist is selected from: a) Compound of general formula (I): in which: - m(l) repres ents 0 or 1; - A(l) represents: and B (l) represents a hydrogen atom A(l) represents a hydrogen atom and B (l) represents: - W(l) – is a nitro genous heterocycle chosen from : - 1-3 ents 1 , 2 or 3; - n(l) represents 1 or 2; - R1 (l) repres ents a halogen atom, a (C lkyl group, a oromethyl radical, a (C 1- C4)alkoxy group or a trifluoromethoxy radical; - R2 (l) represents a hydrogen atom, a halogen atom, a (C 1-C4)alkyl group, a trifluoromethyl radical, a (C 1-C4)alkoxy group, a triflu oromethoxy radical, a COOR (l) group or a CONH 2 group; - R5 (l) represents a group of formula: in which R3 (l) and R4 (l), located on any one of the available positions, independently represent a hydrogen atom, a halogen atom, a (C 1-C4)alkyl or (C 1-C4)alko xy group, a trifluoromethyl or trifluoromethoxy l, a cyano, or a COOH, COO (C lkyl, CONH (l) R7 (l) or NHCOR (l) 2, CONR6 group; - R(l) , R6 (l) and R7 (l) represent independently of each other a (C 1-C6)alkyl group; - in the form of bases or of addit ion salts with acids ; b) Compound of general formula (II): in which: - m(ll) is 0 or 1; - A(ll) is: and B (ll) is a hydrogen atom A(ll) is a hydrogen atom and B (ll) is: - R1 (ll) and R2 (ll) which may be identical or different, are independently a hydrogen or halogen atom, a (C 1-C4) alkyl, (C 1-C4) fluoroalky l, (C 1-C2) perfluoroalky l or (C 1-C4) alkoxy group or a trifluoromethoxy group; - n(ll) is 1 or 2; - R3 (ll) is a group of formula: where R4 (ll) and R5 (ll) , which may be identical or differe nt, are located on any available positions and are independently a hydrogen or halogen atom, a hydroxyl, a (C 1-C4) alkyl, (C 1-C4) fluoroalky l, (C 1-C2) oroalky l or (C 1-C4) alkoxy group, a trifluoromethoxy group, a cyano group, or a COOH, COO (C 1-C4) alkyl, CONH 2, CONR6 (lll) R7 (lll) or NHCOR (lll) group; - R(ll) , R6 (ll) and R7 (ll) are independently of each other a (C 1-C6) alkyl group; in the form of bases or of on salts with acids; c) Compound of general formula (III): in which: - A(lll) re presents a group: - n(lll) ents 1 or 2; - m(lll) represents 0 or 1; - Y(lll) represents a carbon, nitrogen, sulphur or oxygen atom or a single or double bond; - X(lll) , X (lll) 1 and X (lll) 2 represent a carbon, nitrogen, sulphur or oxygen atom, it being understood that at least one of X (lll) , X (lll) 1 and X (lll) 2 is other than a carbon atom; - R(lll) and R1 (lll) , located on any one of the available positions, ndently represent a hydrogen atom, a halogen atom, a (C 1-C4)alkyl group, a (C 1-C4) alkoxy group, a perfluoroalkyl radical, a trifluoromethoxy radical, a cyano, or a COOH, COO (C 1-C4)alkyl, CONR5 (lll) R6 (lll) or NHCOR5 (lll) group; or R1 (lll) represents a group chosen from: the definition of R (lll) ing unchanged; - R3 (lll) and R4 (l ll) , located on any one of the available positions, independently represent a hydrogen atom, a halogen atom, a (C 1-C4)alkyl group, a (C(C 1-C4)-C4) alkoxy group, a perfluoroalky l l, a trifluoromethoxy radical, a cyano, or a COOH, COO (C 1-C4) alkyl, CON R5 (lll) R6 (lll) or NHCOR5 (lll) group; - W(lll) - is a nitrogenous heterocycle chosen from: 2 represents 1 or 2; 3 represents 1, 2 or 3; - R2 (lll) represents a group of formula - R7 (lll) and R8 (lll) , l ocated on any one of the available pos itions, independently represent a hydrogen atom, a halogen atom, a (C 1-C4))alkyl group, a (C 1-C4)alkoxy group, a trifluoromethyl radical, a trifluoromethoxy radical, a cyano, or a COOH, COO (C lkyl, COO (C 1-C4)cycloalkyl, SO (C lkyl, S O2(C 1-C4)alky l, CONH 2, CONR5 (lll) R6 (lll) or NHCOR5 (lll) group; or one of R7 (lll) and R8 (lll) represents a heterocycle chosen from: - Z(lll) represents an oxygen or r atom; - R5 (lll) and R6 (lll) represent a hydrogen or a C1 -C6 alkyl group; - in the form of b ases or of addition salts with acids ; d) Compound of general formula (IV): in which: - n(IV) represents 1 or 2; - m(IV) ents 0 or 1; - A(IV) represents a fused heterocyclic group of formula (Y (IV) ) and B (IV) represents a hydrogen atom; A(IV ) represents a hydrogen atom; and B(IV) represents a fused heterocyclic group of formula (Y (IV) ) The fused heterocycle of formula Y (IV) may be attached to the rest of the molecule via any of the available carbon atoms, and in which: - U(IV) complete s: - either an aromatic or saturated 6 -atom nucleus, containing one or two nitrogen atoms, the nucleus ly being substituted with one or two halogen atoms, one or two (C 1-C4)alkyl or (C 1-C4)alkoxy groups, or one or two perfluoroalky l radicals; - or an aromatic or saturated 5 -atom nucleus, containing a nitrogen, oxygen or sulfur atom, the nucleus possibly being substituted with one or two groups (C 1-C4)alkyl groups; - X(IV) and X1 (IV) represent independently of each other CH or N; - R(IV) and R1 (I V) located on any of the available positions, independently represent a hydrogen atom, a n atom, a group (C 1-C4)alkyl group, (C 1-C4)alkoxy, a oroalky l or trifluoromethoxy radical, a cyano or a group COOH, COO (C 1-C4)alkyl, CONR3 (IV) R4 (IV) or NHC OR3 (IV) ; group; - -W(IV) - is a nitrogenous heterocycle chosen from: - 1-2 represents 1 or 2; - 1-3 represents 1, 2 or 3; - R2 (IV) represents a group of formula: - in which R5 (IV) and R6 (IV) , located on any of the available positions, independently re present a hydrogen atom, a halogen atom, a group (C lkyl or (C 1-C4)alkoxy group, a oromethyl or trifluoromethoxy radical, a cyano or a group COOH, COO (C 1-C4)alkyl, COO (C ycloalkyl, SO (C 1-C4)alkyl, S O2(C 1-C4)alkyl, CONR3 (IV) R4 (IV) , NR3 (IV) R4 (IV) or NHCOR3 (IV) ; or one of the groups R5 (IV) and R6 (IV) may also represent a heterocycle chosen from: - Z(IV) represents an oxygen or sulfur atom; - R3 (IV) and R4 (IV) represent a hydrogen or a group C1-C6 alkyl group, in the form of bases or of add ition salts with acids.
2. Use according to claim 1, wherein said p75 receptor antagonist is selected from: - compound n°1: 1 -[4 -(4 -chloro trifluoromethyl -phenyl) -3,6 -dihydro -2H - pyridin yl] [8 -(5 -fluoro idin yl) -3,8 -diaza -bicyclo[3.2.1 ]oct yl] - ethanone; - compound n°2: 6 -{(3S,5R) -3, 5-Dimethyl [2 -oxo (2 -phenyl -2,4,6,7 - tetrahydropyrazolo[4,3 idin yl)ethyl]piperazin yl}nicotinic acid hydrochloride; - compound n°3: 6 -{(3S,5R) [2 -(4 furan yl -3,6 -dihydro -2H -pyridin yl) oxoethyl] -3,5 hylpiperazin yl}nicotinic acid; - compound n°4: 1 -(2 -phenyl -2,4,6,7 -tetrahydropyrazolo[4,3 -c]pyridin yl) (8 -pyridin yl -3,8 -diazabicyclo[3.2.1]oct yl)ethanone; in the form of a base or of an addition salt with an acid. SANOFI WATERMARK PATENT AND TRADE MARKS ATTORNEY S P39184NZ00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306709.4A EP2606894A1 (en) | 2011-12-20 | 2011-12-20 | Novel therapeutic use of p75 receptor antagonists |
EP11306709.4 | 2011-12-20 | ||
PCT/EP2012/076494 WO2013092918A1 (en) | 2011-12-20 | 2012-12-20 | Novel therapeutic use of p75 receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ626485A NZ626485A (en) | 2016-11-25 |
NZ626485B2 true NZ626485B2 (en) | 2017-02-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6835740B2 (en) | Methods for treating sleep apnea and sleep induced apnea using optically pure (+) norcisapride | |
EP0977558B1 (en) | Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors | |
SK282673B6 (en) | Use of (+) norcisapride, pharmaceutical preparation containing (+ ) norcisapride and its pharmaceutical unitarily dosing form | |
US20110306601A1 (en) | Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression | |
HRP20010075A2 (en) | Methods and compositions for treating gastro-esophageal reflux disease | |
US6559165B1 (en) | Methods for treating bulimia using optically pure (−) norcisapride | |
NZ626485B2 (en) | Novel therapeutic use of p75 receptor antagonists | |
US9763940B2 (en) | Therapeutic use of P75 receptor antagonists | |
US20230355618A1 (en) | Raf inhibitor for treating low grade glioma | |
WO2007005763A2 (en) | Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer | |
OA16932A (en) | Novel therapeutic use of p75 receptor antagonists. | |
TW201332997A (en) | Novel therapeutic use of p75 receptor antagonists | |
RU2508106C2 (en) | Methods and compositions for treating schizophrenia with using atypical neuroleptic combined therapy | |
WO2018197638A1 (en) | Novel use of (5r)-5-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-2-methyl-d-prolinamide | |
RU2508096C2 (en) | Methods and compositions for treating schizophrenia with using neuroleptic combined therapy | |
JP2018035086A (en) | Pharmaceuticals for preventing and/or treating hypoactive bladder | |
WO2009054929A1 (en) | Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease | |
MXPA00012365A (en) | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders | |
EP1464333A2 (en) | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders | |
MXPA00012364A (en) | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders | |
EP1468685A2 (en) | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |